Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates
Portfolio Pulse from
Esperion Therapeutics (ESPR) reported a Q3 loss of $0.15 per share, missing the Zacks Consensus Estimate of a $0.14 loss. This is an improvement from the $0.37 loss per share a year ago.
November 07, 2024 | 1:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Esperion Therapeutics reported a Q3 loss of $0.15 per share, slightly worse than the expected $0.14 loss, but an improvement from last year's $0.37 loss.
The reported loss per share was slightly worse than expected, which could negatively impact the stock price in the short term. However, the improvement from last year's loss may mitigate some negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100